PARSIPPANY, N.J., Nov. 28, 2016 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, FIDIA PHARMA USA INC., introduces newly redesigned packaging for the vaginal hydrating gel, HYALO GYN®. While keeping its current formulation, HYALO GYN®’s new product packaging gives the […]

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

PARSIPPANY, NJ.(BUSINESS WIRE)— Fidia Pharma USA Inc., a wholly owned subsidiary of Fidia Farmaceutici S.p.A. a worldwide leader in the research development and manufacturing of HA based products, has announced that the Center for Medicare & Medicaid Services (“CMS”) has assigned its product HYMOVIS® a unique Healthcare Common Procedure Coding System (“HCPCS”) code, or J-Code. […]

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

HYMOVIS® is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties; new data demonstrating long-term benefits of Hymovis® in alleviating osteoarthritis knee pain and stiffness and improving physical function and quality of life will be presented. PARSIPPANY, N.J., July 5, 2016 – Fidia Farmaceutici S.p.A., a world […]

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

A breakthrough in viscoelastic technology; Hymovis® is an excellent choice for the high-demand patient with OA of the knee PARSIPPANY, N.J., May 2016 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, Fidia Pharma USA Inc., announced that Hymovis® (high molecular […]

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

Hymovis®, which is being launched in the U.S, is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties PARSIPPANY, N.J., February 25, 2016 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, Fidia […]

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

Hymovis®, which was recently approved by the FDA in the U.S., is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties PARSIPPANY, N.J., Nov. 2, 2015 – Fidia Farmaceutici, a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned […]

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

PARSIPPANY, N.J. & ABANO TERME, Italy July 07, 2014 — Fidia Pharma USA Inc., a wholly-owned subsidiary of Fidia Farmaceutici SpA, an international integrated company and recognized leader in hyaluronic acid-based products, announced today the completion of the establishment of its operations in the United States. Effective July 2014, the company’s sales force, previously operating […]

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

ABANO TERME, Italy and PARSIPPANY, New Jersey, January 6, 2014 /PRNewswire/ — FIDIA Farmaceutici S.p.A., the Italian pharmaceutical company leader in hyaluronic acid (HY) – based products, announced today that they will be present at the 32nd Annual J. P. Morgan Investors Healthcare Conference. The conference will take place on Monday, January 13, 2014, through […]

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

Fidia Pharma USA, Inc. will be exhibiting at the Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) in New Orleans, LA, March 11-15, 2014. Please come and see us at booth 973. We will be exhibiting our flagship product HYALGAN® (sodium hyaluronate, intra-articular injections for the treatment of pain in osteoarthritis of the […]

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

Fidia Pharma USA Inc will be exhibiting at the Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) in Chicago, IL, March 19-23 2013. Please come and see us at booth 3706. We will be exhibiting our flagship product HYALGAN® (sodium hyaluronate, intra-articular injections for the treatment of pain in osteoarthritis of the knee. […]

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness